Overview

Discovery and Development

Zydus has established robust capabilities across the research continuum—from early discovery and pre-clinical development to clinical research and regulatory pathways. Zydus has developed novel therapies such as Lipaglyn (Saroglitazar), India’s first indigenously discovered NCE, and Desidustat, an oral therapy for anaemia in chronic kidney disease, alongside a growing portfolio of monoclonal antibodies, antibody drug conjugates and next-generation biosimilars.

Technology and Innovation

Research at Zydus is further strengthened by the adoption of advanced technologies, including digital tools, data analytics and platform-based approaches to accelerate development timelines and improve precision. Zydus continues to invest in its research ecosystem through collaborations, partnerships and specialised centres of excellence. This integrated and innovation-driven approach enables Zydus to translate scientific discovery into accessible, high-quality therapies, expanding access and improving patient outcomes worldwide.

Collaborate with Us

Zydus actively seeks to build meaningful collaborations that advance research, accelerate innovation and expand access to healthcare solutions. With a strong foundation in science and an integrated research ecosystem, the Company partners across the pharmaceutical value chain to co-create and develop differentiated therapies.

Zydus is open to exploring opportunities across collaborative research and development, in-licensing of technologies and new molecular entities, as well as out-licensing and co-development of its drug candidates. These partnerships are aimed at addressing unmet medical needs, leveraging complementary capabilities and bringing innovative therapies closer to patients worldwide.